Anemia, Ineffective Erythropoiesis, and Hepcidin: Interacting Factors in Abnormal Iron Metabolism Leading to Iron Overload in β-thalassemia

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2010 Nov 16

PMID 21075282

Citations 41

Authors

Sara Gardenghi

Robert W Grady

Stefano Rivella

Affiliations

Soon will be listed here.

Abstract

β-Thalassemia is a genetic disorder caused by mutations in the β-globin gene and characterized by chronic anemia caused by ineffective erythropoiesis, and accompanied by a variety of serious secondary complications such as extramedullary hematopoiesis, splenomegaly, and iron overload. In the past few years, numerous studies have shown that such secondary disease conditions have a genetic basis caused by the abnormal expression of genes with a role in controlling erythropoiesis and iron metabolism. In this article, the most recent discoveries related to the mechanism(s) responsible for anemia/ineffective erythropoiesis and iron overload are discussed in detail. Particular attention is paid to the pathway(s) controlling the expression of hepcidin, which is the main regulator of iron metabolism, and the Epo/EpoR/Jak2/Stat5 signaling pathway, which regulates erythropoiesis. Better understanding of how these pathways function and are altered in β-thalassemia has revealed several possibilities for development of new therapeutic approaches to treat of the complications of this disease.

Citing Articles

Pancreatic Volume in Thalassemia: Determinants and Association with Alterations of Glucose Metabolism.

Meloni A, Restaino G, Positano V, Pistoia L, Keilberg P, Santodirocco M Diagnostics (Basel). 2025; 15(5).

PMID: 40075815 PMC: 11899254. DOI: 10.3390/diagnostics15050568.

Cardiac injury caused by iron overload in thalassemia.

Fu C, Yang X Front Pediatr. 2025; 13:1514722.

PMID: 39931654 PMC: 11808023. DOI: 10.3389/fped.2025.1514722.

Mechanism and application prospect of ferroptosis inhibitors in improving osteoporosis.

Wang J, Chen T, Gao F Front Endocrinol (Lausanne). 2024; 15:1492610.

PMID: 39735645 PMC: 11671246. DOI: 10.3389/fendo.2024.1492610.

Heme oxygenase 1 in erythropoiesis: an important regulator beyond catalyzing heme catabolism.

Liu R, Zhang X, Nie L, Sun S, Liu J, Chen H Ann Hematol. 2023; 102(6):1323-1332.

PMID: 37046065 DOI: 10.1007/s00277-023-05193-7.

Host and microbiota derived extracellular vesicles: Crucial players in iron homeostasis.

Daou Y, Falabregue M, Pourzand C, Peyssonnaux C, Edeas M Front Med (Lausanne). 2022; 9:985141.

PMID: 36314015 PMC: 9606470. DOI: 10.3389/fmed.2022.985141.

References

Kearney S, Nemeth E, Neufeld E, Thapa D, Ganz T, Weinstein D . Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2005; 48(1):57-63. DOI: 10.1002/pbc.20616. View

Levine R . Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol. 2009; 22(4):489-94. DOI: 10.1016/j.beha.2009.08.006. View

De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch E, Roetto A . Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica. 2006; 91(10):1336-42. View

Li H, Rybicki A, Suzuka S, von Bonsdorff L, Breuer W, Hall C . Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010; 16(2):177-82. DOI: 10.1038/nm.2073. View

Taher A, Mehio G, Ismaeel H, Cappellini M . Stroke in thalassemia: a dilemma. Am J Hematol. 2008; 83(4):343. DOI: 10.1002/ajh.21117. View

Fibach E, Rachmilewitz E . The role of oxidative stress in hemolytic anemia. Curr Mol Med. 2008; 8(7):609-19. DOI: 10.2174/156652408786241384. View

Tanno T, Rabel A, Lee Y, Yau Y, Leitman S, Miller J . Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion. 2010; 50(7):1532-5. PMC: 3282986. DOI: 10.1111/j.1537-2995.2010.02601.x. View

Nemeth E, Valore E, Territo M, Schiller G, Lichtenstein A, Ganz T . Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2002; 101(7):2461-3. DOI: 10.1182/blood-2002-10-3235. View

Giardina P, Grady R . Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001; 38(4):360-6. DOI: 10.1016/s0037-1963(01)90030-7. View

10.

Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth M . Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41(4):478-81. DOI: 10.1038/ng.320. View

11.

Ciavatta D, Ryan T, Farmer S, Townes T . Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc Natl Acad Sci U S A. 1995; 92(20):9259-63. PMC: 40964. DOI: 10.1073/pnas.92.20.9259. View

12.

Rivella S . Ineffective erythropoiesis and thalassemias. Curr Opin Hematol. 2009; 16(3):187-94. PMC: 3703923. DOI: 10.1097/MOH.0b013e32832990a4. View

13.

Li K, Miller C, Hegde S, Wojchowski D . Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit. J Biol Chem. 2003; 278(42):40702-9. DOI: 10.1074/jbc.M307182200. View

14.

Weatherall D . Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001; 2(4):245-55. DOI: 10.1038/35066048. View

15.

Goswami T, Andrews N . Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006; 281(39):28494-8. DOI: 10.1074/jbc.C600197200. View

16.

Jenkins Z, Hagar W, Bowlus C, Johansson H, Harmatz P, Vichinsky E . Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol. 2007; 24(4):237-43. DOI: 10.1080/08880010701360700. View

17.

Feder J, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy D, Basava A . A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13(4):399-408. DOI: 10.1038/ng0896-399. View

18.

Cohen A, Galanello R, Pennell D, Cunningham M, Vichinsky E . Thalassemia. Hematology Am Soc Hematol Educ Program. 2004; :14-34. DOI: 10.1182/asheducation-2004.1.14. View

19.

Tanno T, Porayette P, Sripichai O, Noh S, Byrnes C, Bhupatiraju A . Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114(1):181-6. PMC: 2710947. DOI: 10.1182/blood-2008-12-195503. View

20.

Libani I, Guy E, Melchiori L, Schiro R, Ramos P, Breda L . Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008; 112(3):875-85. PMC: 2481539. DOI: 10.1182/blood-2007-12-126938. View